礼来制药于4月22日公布,将以54亿美元收购诺华动物保健业务。此次收购将使礼来制药原有的动物保健业务(Elanco)获得进一步的成长和多元化。完成此次收购之后,就总体收入而言,Elanco将成为全球第二大动物保健公司。作为礼来制药五大事业部之一,在过去5年里已经完成在战略布局上的诸多调整,并取得了良好收益(相关报道详见本刊2014年第8期)。此次交易将极大地拓展并补充Elanco的产品组成、强化研发和生产能力,并优化在关键区域的 Eli Lilly and Company announced on April 22 that it will acquire Novartis Animal Health for $ 5.4 billion. The acquisition will allow Eli Lilly’s original animal health business (Elanco) to further grow and diversify. After the acquisition, Elanco will become the second largest animal health company in the world in terms of overall revenue. As one of Eli Lilly’s top five divisions, it has completed many adjustments in its strategic layout in the past five years and has achieved good returns. (For related reports, see Issue 8, Issue 2014, 2014). The transaction will greatly expand and complement Elanco’s product portfolio, enhance R & D and manufacturing capabilities, and optimize performance in key areas